U.S. treatment guidelines: new version, October 2005.The October 6, 2005 guidelines have relatively few changes, but they are important for some patients. For those beginning antiretrovirals, the guidelines now say that the combination of an NNRTI NNRTI Non-nucleoside reverse transcriptase inhibitor, see there + didanosine didanosine /di·dan·o·sine/ (-dan´o-sen) 2, an analogue of dideoxyadenosine; an antiretroviral agent used for the treatment of advanced HIV-1 infection and acquired immunodeficiency syndrome, administered orally. plus tenofovir should not be used, due to virologic failure virologic failure Antiretroviral therapy failure, see there and development of resistance. And the guidelines do not recommend ritonavir-boosted tipranavir in treatment-naive patients, due to the lack of clinical-trial data. For experienced patients, "This section has been updated to redefine the goal of antiretroviral antiretroviral /an·ti·ret·ro·vi·ral/ (-ret´ro-vi?ral) effective against retroviruses, or an agent with this quality. an·ti·ret·ro·vi·ral adj. therapy in the management of treatment-experienced patients with virologic failure and to review the role of more potent ritonavir-boosted protease inhibitors Protease Inhibitors Definition A protease inhibitor is a type of drug that cripples the enzyme protease. An enzyme is a substance that triggers chemical reactions in the body. such as tipranavir with or without enfuvirtide in these patients." Much of the guidelines material is presented in a series of tables. The second page, titled "What's New in the Document," also notes the tables that have been changed. This and other U.S. government guidelines are available at http://www.aidsinfo.nih.gov/guidelines/ |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion